NGX-4010 Capsaicin Patch for Neuropathic Pain Treatment
Collecte de données
Infection par le virus varicelle-zona+31
+ Infections transmises par le sang
+ Maladies génito-urinaires
Étude thérapeutique
Résumé
This is a study focused on treating neuropathic pain, a type of pain caused by damage to the nerves. It's specifically designed for individuals who have recently participated in a previous study (NeurogesX Study C111) and received treatment with a medication called NGX-4010, or Capsaicin Patch. The goal is to further explore the potential benefits of this treatment for neuropathic pain. In this study, participants will continue to receive the NGX-4010 treatment, which comes in the form of a patch. The study will monitor the effects of the treatment over time to understand its long-term impact on neuropathic pain. It's important to note that as an open-label study, everyone involved knows which treatment is being used.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Key Eligibility Criteria: * Must have completed NeurogesX Study C111 and received treatment with NGX-4010 (Capsaicin Patch) within 12 weeks (up to +7 days) before entry into Study C114. * Demonstrated adherence to protocol requirements during Study C111, and willing and able to comply with protocol requirements for the duration of the study participation. * Must not have had any serious adverse experience since enrollment in Study C111, whether or not considered to be study drug-related. * Must have intact skin at the treatment area. * Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (36 weeks). * Must not use topical pain medications on painful areas. * Must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed. * No history or current problem with substance abuse.